What is QURE's market cap?

$1.60B, based on the Nov 4 close of $23.03.

Does uniQure pay a dividend?

No regular cash dividend has been paid in the last year.

How much of QURE is sold short?

8.7M shares, 13.2% of float, as of Oct 15, 2026.

What sector is QURE in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · QUREHealthcarePharmaceuticals

uniQure N.V. (QURE)

$23.03−3.52%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$22.93▼ 33.13% in range

Nov 3, 2025Low $9.03 · High $51.05Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

uniQure closed at $23.03 on Nov 4, down 3.52%, 54.9% below its 52-week closing high. Volume of 2.7M shares was 1.41× its 20-day average (above normal).

Split-adjusted performance: -0.1% over one month, +0.9% over six months, -32.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $5.84M, up 11.0% from a year earlier, with a net margin of -1387.8%.

Short interest was 8.7M shares at the Oct 15 settlement (13.2% of float, 3.8 days to cover).

Market cap$1.60B69.4M shares

Revenue · quarter$5.8M+11.0% YoY

Diluted EPS$-1.22—

P/E · TTM—P/S 85.6×

Net margin-1,387.8%Gross 94.0%

Dividend yieldNone

52-week range9.03 – 51.05−54.9% from high

Volume2.7M1.41× 20-day avg

Volatility · 60d109.1%Annualised

Short % of float13.2%3.8 days to cover

Net cash$760.2MCash $810.3M

Next earnings—Not scheduled

Split-adjusted performance

1W −7.8%1M −0.1%3M −49.2%6M +0.9%YTD −3.8%1Y −32.8%3Y +305.5%5Y −20.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum73

Revenue growth58

Net margin17

Value (low P/E)—

Size77

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short8.7M+0.1% vs prior

Days to cover3.8Settled Oct 15

% of float13.2%

Short vol. 10d37.7%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
QUREuniQure	$23.03	−3.52%	+0.9%	+11.0%	−1387.8%	—	$1.60B
PAHCPhibro Animal Health	$39.43	+4.73%	−32.6%	+4.8%	5.5%	16.1	$1.60B	Compare
OCULOcular Therapeutix	$7.14	+4.69%	−26.5%	+0.1%	−584.5%	—	$1.57B	Compare
SUPNSupernus	$28.21	+0.21%	−45.2%	+18.0%	9.2%	—	$1.64B	Compare
ANIPANI Pharmaceuticals	$71.65	−0.87%	−14.8%	+25.9%	8.6%	16.5	$1.65B	Compare
KLRAKailera Therapeutics	$12.80	+1.75%	—	—	—	—	$1.66B	Compare
NUVBNuvation Bio	$4.73	+0.85%	−6.2%	+555.6%	−198.3%	—	$1.66B	Compare
INVAInnoviva	$21.26	+1.58%	−5.6%	+19.3%	−69.8%	4.3	$1.54B	Compare
RAREUltragenyx Pharmaceutical	$17.16	+3.19%	−33.8%	+28.1%	−43.0%	—	$1.69B	Compare

News about uniQure

All news →

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their RightsGlobeNewswire Inc. · Sep 30, 2026▼ Negative uniQure Plunges on Additional Data From Huntington's Disease StudyZacks Investment Research · Sep 30, 2026▼ Negative QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C.GlobeNewswire Inc. · Sep 29, 2026▼ Negative uniQure Announces Pricing of Upsized $225 Million Public OfferingGlobeNewswire Inc. · Jun 24, 2026▲ Positive Numero AI and Royu Merge to Redefine How Finance Teams OperateBenzinga · May 21, 2026Neutral

Quick answers

What does uniQure do?: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases.
What is QURE's market cap?: $1.60B, based on the Nov 4 close of $23.03.
Does uniQure pay a dividend?: No regular cash dividend has been paid in the last year.
How much of QURE is sold short?: 8.7M shares, 13.2% of float, as of Oct 15, 2026.
What sector is QURE in?: Healthcare, in the Pharmaceuticals industry.

About uniQure

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

HQ: Amsterdam, 221 employeesListed Feb 5, 2014uniqure.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology